In 2023, Similasan Allergy Eye Relief Drops were removed from stores following FDA intervention concerning unapproved drug claims and manufacturing issues. The company halted sales and recalled products, leading to a $3.575 million class-action settlement in 2024, benefitting consumers who purchased the drops from 2017 to 2025.